159 related articles for article (PubMed ID: 9788259)
1. c-Met expression of thyroid tissue with special reference to papillary carcinoma.
Oyama T; Ichimura E; Sano T; Kashiwabara K; Fukuda T; Nakajima T
Pathol Int; 1998 Oct; 48(10):763-8. PubMed ID: 9788259
[TBL] [Abstract][Full Text] [Related]
2. Expression of the hepatocyte growth factor and c-met in normal thyroid, non-neoplastic, and neoplastic nodules.
Trovato M; Villari D; Bartolone L; Spinella S; Simone A; Violi MA; Trimarchi F; Batolo D; Benvenga S
Thyroid; 1998 Feb; 8(2):125-31. PubMed ID: 9510120
[TBL] [Abstract][Full Text] [Related]
3. Immunostaining for Met/HGF receptor may be useful to identify malignancies in thyroid lesions classified suspicious at fine-needle aspiration biopsy.
Ippolito A; Vella V; La Rosa GL; Pellegriti G; Vigneri R; Belfiore A
Thyroid; 2001 Aug; 11(8):783-7. PubMed ID: 11525273
[TBL] [Abstract][Full Text] [Related]
4. Distinctive expression of STAT3 in papillary thyroid carcinomas and a subset of follicular adenomas.
Trovato M; Grosso M; Vitarelli E; Ruggeri RM; Alesci S; Trimarchi F; Barresi G; Benvenga S
Histol Histopathol; 2003 Apr; 18(2):393-9. PubMed ID: 12647789
[TBL] [Abstract][Full Text] [Related]
5. Difference in patterns of Met expression in papillary thyroid carcinomas and nonneoplastic thyroid tissue.
Fluge Ø ; Haugen DR; Lillehaug JR; Varhaug JE
World J Surg; 2001 May; 25(5):623-31. PubMed ID: 11369990
[TBL] [Abstract][Full Text] [Related]
6. Retinoblastoma expression in thyroid neoplasms.
Anwar F; Emond MJ; Schmidt RA; Hwang HC; Bronner MP
Mod Pathol; 2000 May; 13(5):562-9. PubMed ID: 10824929
[TBL] [Abstract][Full Text] [Related]
7. Met protein and hepatocyte growth factor (HGF) in papillary carcinoma of the thyroid: evidence for a pathogenetic role in tumourigenesis.
Ruco LP; Stoppacciaro A; Ballarini F; Prat M; Scarpino S
J Pathol; 2001 May; 194(1):4-8. PubMed ID: 11329134
[TBL] [Abstract][Full Text] [Related]
8. Negative/low expression of the Met/hepatocyte growth factor receptor identifies papillary thyroid carcinomas with high risk of distant metastases.
Belfiore A; Gangemi P; Costantino A; Russo G; Santonocito GM; Ippolito O; Di Renzo MF; Comoglio P; Fiumara A; Vigneri R
J Clin Endocrinol Metab; 1997 Jul; 82(7):2322-8. PubMed ID: 9215314
[TBL] [Abstract][Full Text] [Related]
9. HGF/C-MET system pathways in benign and malignant histotypes of thyroid nodules: an immunohistochemical characterization.
Ruggeri RM; Vitarelli E; Barresi G; Trimarchi F; Benvenga S; Trovato M
Histol Histopathol; 2012 Jan; 27(1):113-21. PubMed ID: 22127603
[TBL] [Abstract][Full Text] [Related]
10. Over-expression of hepatocyte growth factor/scatter factor (HGF/SF) and the HGF/SF receptor (cMET) are associated with a high risk of metastasis and recurrence for children and young adults with papillary thyroid carcinoma.
Ramirez R; Hsu D; Patel A; Fenton C; Dinauer C; Tuttle RM; Francis GL
Clin Endocrinol (Oxf); 2000 Nov; 53(5):635-44. PubMed ID: 11106926
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical localisation of RET and p53 mutant protein of thyroid lesions in a North-Eastern Malaysian population and its prognostic implications.
Omar E; Madhavan M; Othman NH
Pathology; 2004 Apr; 36(2):152-9. PubMed ID: 15203751
[TBL] [Abstract][Full Text] [Related]
12. The expression and role of serum response factor in papillary carcinoma of the thyroid.
Kim HJ; Kim KR; Park HS; Jang KY; Chung MJ; Shong M; Moon WS
Int J Oncol; 2009 Jul; 35(1):49-55. PubMed ID: 19513551
[TBL] [Abstract][Full Text] [Related]
13. MUC1 mucin gene, transcripts, and protein in adenomas and papillary carcinomas of the thyroid.
Bièche I; Ruffet E; Zweibaum A; Vildé F; Lidereau R; Franc B
Thyroid; 1997 Oct; 7(5):725-31. PubMed ID: 9349575
[TBL] [Abstract][Full Text] [Related]
14. Ret oncogene activation in papillary thyroid carcinoma: prevalence and implication on the histological parameters.
Lam AK; Montone KT; Nolan KA; Livolsi VA
Hum Pathol; 1998 Jun; 29(6):565-8. PubMed ID: 9635675
[TBL] [Abstract][Full Text] [Related]
15. Keratin subsets in papillary and follicular thyroid lesions. A paraffin section analysis with diagnostic implications.
Miettinen M; Kovatich AJ; Kärkkäinen P
Virchows Arch; 1997 Dec; 431(6):407-13. PubMed ID: 9428928
[TBL] [Abstract][Full Text] [Related]
16. NDRG1 protein overexpression in malignant thyroid neoplasms.
Gerhard R; Nonogaki S; Fregnani JH; Soares FA; Nagai MA
Clinics (Sao Paulo); 2010 Jun; 65(8):757-62. PubMed ID: 20835551
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of c-Met protein in human thyroid tumors correlated with lymph node metastasis and clinicopathologic stage.
Chen BK; Ohtsuki Y; Furihata M; Takeuchi T; Iwata J; Liang SB; Sonobe H
Pathol Res Pract; 1999; 195(6):427-33. PubMed ID: 10399184
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of HGF and c-MET is associated with subclinical central lymph node metastasis in papillary thyroid microcarcinoma.
Koo BS; Kim JM; Seo ST; Yoon YH; Kwon KR; Kim SH; Kwon HW; Bae WJ; Lim YC
Ann Surg Oncol; 2014 Jul; 21(7):2310-7. PubMed ID: 24562934
[TBL] [Abstract][Full Text] [Related]
19. Activation of the hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: biological effects of HGF in thyroid cancer cells depend on Met expression levels.
Mineo R; Costantino A; Frasca F; Sciacca L; Russo S; Vigneri R; Belfiore A
Endocrinology; 2004 Sep; 145(9):4355-65. PubMed ID: 15192042
[TBL] [Abstract][Full Text] [Related]
20. ret/PTC expression may be associated with local invasion of thyroid papillary carcinoma.
Miki H; Kitaichi M; Masuda E; Komaki K; Yamamoto Y; Monden Y
J Surg Oncol; 1999 Jun; 71(2):76-81; discussion 81-2. PubMed ID: 10389862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
